

John Neil Primrose

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3386668/publications.pdf>

Version: 2024-02-01

63
papers

7,954
citations

159585

30
h-index

149698

56
g-index

65
all docs

65
docs citations

65
times ranked

8500
citing authors

#	ARTICLE	IF	CITATIONS
1	Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. <i>Lancet, The</i> , 2008, 371, 1007-1016.	13.7	1,759
2	Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2013, 14, 1208-1215.	10.7	1,017
3	Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. <i>Lancet Oncology, The</i> , 2019, 20, 663-673.	10.7	773
4	Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. <i>Clinical Epidemiology</i> , 2012, 4, 283.	3.0	459
5	Effect of 3 to 5 Years of Scheduled CEA and CT Follow-up to Detect Recurrence of Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 263.	7.4	384
6	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. <i>Lancet Oncology, The</i> , 2014, 15, 601-611.	10.7	371
7	Single-Centre Comparative Study of Laparoscopic Versus Open Right Hepatectomy. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 818-823.	1.7	350
8	Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 1015-1027.	1.6	301
9	The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection. <i>Annals of Surgery</i> , 2020, 271, 1-14.	4.2	294
10	Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA). <i>Annals of Surgery</i> , 2019, 269, 10-17.	4.2	211
11	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. <i>BMC Cancer</i> , 2015, 15, 564.	2.6	182
12	Short- and long-term outcomes after laparoscopic and open hepatic resection: systematic review and meta-analysis. <i>Hpb</i> , 2011, 13, 295-308.	0.3	178
13	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2020, 21, 398-411.	10.7	152
14	Laparoscopic versus open major hepatectomy: a systematic review and meta-analysis of individual patient data. <i>Surgery</i> , 2018, 163, 985-995.	1.9	147
15	Exosomal microRNAs derived from colorectal cancer-associated fibroblasts: role in driving cancer progression. <i>Aging</i> , 2017, 9, 2666-2694.	3.1	112
16	The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. <i>Gut</i> , 2016, 65, 977-989.	12.1	111
17	Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983). <i>Annals of Surgery</i> , 2012, 255, 534-539.	4.2	91
18	Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 651-662.	4.2	91

#	ARTICLE	IF	CITATIONS
19	Outcome and Learning Curve in 159 Consecutive Patients Undergoing Total Laparoscopic Hemihepatectomy. <i>JAMA Surgery</i> , 2016, 151, 923.	4.3	88
20	Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence. <i>Pancreatology</i> , 2018, 18, 962-970.	1.1	81
21	Current standards and future perspectives in adjuvant treatment for biliary tract cancers. <i>Cancer Treatment Reviews</i> , 2020, 84, 101936.	7.7	73
22	A top-down view of the tumor microenvironment: structure, cells and signaling. <i>Frontiers in Cell and Developmental Biology</i> , 2015, 3, 33.	3.7	70
23	Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 2048-2057.	1.6	65
24	Assessment of the financial implications for laparoscopic liver surgery: a single-centre UK cost analysis for minor and major hepatectomy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013, 27, 2542-2550.	2.4	54
25	Site and Stage of Colorectal Cancer Influence the Likelihood and Distribution of Disease Recurrence and Postrecurrence Survival. <i>Annals of Surgery</i> , 2016, 263, 1143-1147.	4.2	53
26	A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent. <i>Health Technology Assessment</i> , 2017, 21, 1-86.	2.8	44
27	Myosteatosis is associated with poor physical fitness in patients undergoing hepatopancreatobiliary surgery. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 860-871.	7.3	42
28	Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial. <i>Oncotarget</i> , 2017, 8, 93856-93866.	1.8	42
29	Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs. <i>Oncotarget</i> , 2015, 6, 7262-7279.	1.8	35
30	Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 144, 368-381.	2.8	34
31	A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3504-3504.	1.6	34
32	EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3508-3508.	1.6	27
33	Lung metastasectomy in colorectal cancer: Is this surgery effective in prolonging life?. <i>Respirology</i> , 2010, 15, 742-746.	2.3	26
34	Assessment of Nuclear ZEB2 as a Biomarker for Colorectal Cancer Outcome and TNM Risk Stratification. <i>JAMA Network Open</i> , 2018, 1, e183115.	5.9	24
35	Intrahepatic cholangiocarcinoma as the new field of implementation of laparoscopic liver resection programs. A comparative propensity score-based analysis of open and laparoscopic liver resections. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 1851-1862.	2.4	24
36	Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1. <i>Scientific Reports</i> , 2016, 6, 32417.	3.3	20

#	ARTICLE	IF	CITATIONS
37	Natural killer cell maturation markers in the human liver and expansion of an NKG2C+KIR+ population. <i>Lancet, The</i> , 2015, 385, S45.	13.7	19
38	What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial. <i>Health Technology Assessment</i> , 2017, 21, 1-60.	2.8	19
39	Epithelial to mesenchymal transition influences fibroblast phenotype in colorectal cancer by altering miR-200 levels in extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	12.2	18
40	Evaluation and management of incidental gallbladder cancer. <i>Chinese Clinical Oncology</i> , 2019, 8, 37-37.	1.2	13
41	Hepatic Resection Following Selective Internal Radiation Therapy for Colorectal Cancer Metastases in the FOXFIRE Clinical Trial: Clinical Outcomes and Distribution of Microspheres. <i>Cancers</i> , 2019, 11, 1155.	3.7	11
42	Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. <i>British Journal of Cancer</i> , 2016, 115, 420-424.	6.4	9
43	The value of tumour debulking for patients with extensive multi-organ metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2018, 103, 160-164.	2.8	8
44	Cetuximab Is Contraindicated in the Perioperative Treatment of Colorectal Liver Metastases. <i>Journal of Clinical Oncology</i> , 2015, 33, 2405-2406.	1.6	7
45	Comprehensive Imaging Characterization of Colorectal Liver Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 730854.	2.8	7
46	Cetuximab for resectable colorectal liver metastasis: New EPOC trial – Author's reply. <i>Lancet Oncology, The</i> , 2014, 15, e306.	10.7	3
47	Development and validation of a model to predict outcomes of colon cancer surveillance. <i>Cancer Causes and Control</i> , 2019, 30, 767-778.	1.8	3
48	Mir-31-3p as a predictive biomarker of cetuximab effects in a post hoc analysis of new EPOC phase III trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3523-3523.	1.6	3
49	Patterns of progression, treatment of progressive disease, and postprogression survival in the new EPOC study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3556-3556.	1.6	3
50	Laparoscopic versus open resections in the posterosuperior liver segments within an enhanced recovery programme (ORANGE Segments): study protocol for a multicentre randomised controlled trial. <i>Trials</i> , 2022, 23, 206.	1.6	3
51	The impact of enhanced recovery on open and laparoscopic liver resections. <i>Updates in Surgery</i> , 2020, 72, 649-657.	2.0	2
52	Hepatic metastases resection after cetuximab: are we missing something? – Authors' reply. <i>Lancet Oncology, The</i> , 2020, 21, e229.	10.7	1
53	Comment on –Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position–. <i>British Journal of Cancer</i> , 2021, 124, 678-678.	6.4	1
54	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1): A randomized, multidisciplinary, multinational phase III trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4140-TPS4140.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Association between density of tumor infiltrating lymphocytes and disease-free survival (DFS) in patients with resected stage I-III colorectal cancer in the FACS randomized trial.. Journal of Clinical Oncology, 2018, 36, 3573-3573.	1.6	1
56	Reply to J. Edeline et al. Journal of Clinical Oncology, 0, , .	1.6	1
57	Hdm2 Recruits the Hypoxia Sensitive Transcriptional Co-Repressor CtBP2 to Negatively Regulate p53-Dependant Transcription. Clinical Science, 2003, 104, 29P-29P.	0.0	0
58	Surgical leadership: the British concept. Innovative Surgical Sciences, 2019, 4, 65-67.	0.7	0
59	Adjuvant Chemotherapy in Resected Biliary Tract Cancer. Annals of Surgical Oncology, 2020, 27, 2127-2129.	1.5	0
60	Intratumoural immune signature to identify patients with primary colorectal cancer who do not require follow-up after resection: an observational study. Health Technology Assessment, 2021, 25, 1-32.	2.8	0
61	Use of FLIM histology-based HER2-HER3 heterodimer quantification and a Bayesian latent class proportional hazards model to predict cetuximab response in the COIN and new EPOC trials.. Journal of Clinical Oncology, 2015, 33, e14535-e14535.	1.6	0
62	Association between c-Met expression, miR-31-3p expression and progression free survival in the New EPOC study.. Journal of Clinical Oncology, 2015, 33, 3545-3545.	1.6	0
63	P-P47â€¦Impact of neoadjuvant chemotherapy on postoperative pancreatic fistula in patients undergoing pancreaticoduodenectomy. British Journal of Surgery, 2021, 108, .	0.3	0